Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
German life sciences company Bayer was trading 7% lower in mid-afternoon trading on Thursday after presenting its first-quarter financial results and latest outlook for 2023 as a whole. 11 May 2023
Pharmaceutical
French drugmaker Servier has secured European approval for Tibsovo (ivosidenib) in two indications, making it the first and only IDH1 blocker to be available in the region. 11 May 2023
Pharmaceutical
Japan’s largest drugmaker Takeda has announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products. 11 May 2023
Biotechnology
UK-based cancer immunotherapy company Immodulon has named Richard Davies its new chairman of the board, appointed Gertjan Bartlema chief executive and brought in Peter Greaney as chief business officer. 10 May 2023
Biotechnology
Shares of UK biotech Bicycle Therapeutics rode up 8.6% to $24.30 by mid-morning US trading, on the news of a potentially lucrative deal with Germany’s Bayer. 10 May 2023
Biotechnology
Announcing its first M&A deal in more than a year, California, USA-based Gilead Sciences said yesterday that it has acquired privately-held US biotech XinThera. 10 May 2023
Biotechnology
Privately-held Chinese biotech Zion Pharma revealed that Swiss pharms giant Roche has acquired the global rights to Zion’s lead program, ZN-A-1041, an orally administered selective tyrosine kinase inhibitor targeting the human epidermal growth factor receptor 2 (HER2). 10 May 2023
Biotechnology
US drugmaker EQRx had already signalled a shift away from its foundational principle to develop and deliver innovative medicines to patients at radically lower prices. 9 May 2023
Biotechnology
The World Health Organization’s (WHO) declaration on Friday that the COVID-19 global emergency status has ended, and that the virus should now be managed alongside other infectious diseases, formally brings to an end what has been an uncertain and difficult time for much of the world. 9 May 2023
Biotechnology
Japanese drugmaker Eisai has entered into an agreement with Chinese firm Bliss Biopharmaceutical to develop an antibody-drug conjugate (ADC). 9 May 2023
Generics
India’s Venus Remedies has won separate marketing authorizations for off-patent cancer drugs in the Philippines and Iraq. 9 May 2023
Biotechnology
US antibody-drug conjugate (ADC) specialist ImmunoGen closed 123% higher after trading on Wednesday. 4 May 2023
Generics
Sandoz, the soon to be divested generics and biosimilars business of Swiss pharma giant Novartis, today announced the signing of a distribution and collaboration agreement with Adalvo for exclusive Sandoz rights to commercialize six products in the USA across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary. 4 May 2023
Biotechnology
The European Commission (EC) has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for a number of new lymphoma indications. 3 May 2023
Biotechnology
Total investment in biopharma M&A in the first quarter of 2023 was over four times the equivalent value for first quarter 2022, including the first megadeal since December 2020 with Pfizer paying $43 billion to acquire Seagen. 3 May 2023
Pharmaceutical
Despite a strong opening, New York-based pharma giant Pfizer saw its shares fall in price over the morning on Tuesday, following the release of its financial results for the first quarter of 2023. 2 May 2023
Biotechnology
US healthcare giant Johnson & Johnson’s Janssen Biotech subsidiary has entered into a worldwide collaboration and license agreement with China-based Cellular Biomedicine Group to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. 2 May 2023
Biotechnology
Breyanzi works in broadest array of B-cell malignancies of any CD19-directed CAR-T therapy, says BMS
Bristol Myers Squibb has announced positive top-line results from two studies on Breyanzi (lisocabtagene maraleucel), its CD19-directed CAR-T cell therapy. 2 May 2023
Biotechnology
Privately-held Australian biotech Cartherics has granted Shunxi Holding Group a license to develop, manufacture and commercialize its autologous CAR-T cell product, CTH-004, for multiple solid tumors including ovarian cancer in Greater China. 28 April 2023
Biotechnology
As with many biopharma firms, Gilead Sciences reported a drop in first-quarter revenue this year due to a decline in sales of a COVID-19 treatment. 28 April 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze